Navigation Links
Eurand's Zentase Effective in Treating Exocrine Pancreatic,Insufficiency, Studies Show

.S. Federal Food, Drug and Cosmetic Act in 1938 and consequently none of the currently available products are marketed under a NDA approved by the FDA. In April, 2004, the FDA mandated that all manufacturers of EPI drug products file a NDA and receive approval for their products by April 2008 or be subject to regulatory action.

One of the FDA requirements to submit an NDA for a PEP is the elimination of product overfill allowed under current guidelines. Currently, individual enzyme doses can be overfilled up to 165 percent of label claim(3) to compensate for the breakdown of enzymes over time and to ensure that each capsule contains at least 90 percent of the label claim at the end of the product's shelf life. As a result, patients taking PEPs may be unknowingly over or under treating their disease by using a product with variable potency. This variability can put patients at risk for colonic strictures with overtreatment or malnutrition with undertreatment.

As a highly-stable product, Zentase does not require overfill. It will be filled at 100 percent of label claim, with a minimum of 2-years shelf life, to ensure consistent dosage and maintain treatment levels over time.

About Eurand

Eurand is a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug formulation technologies. Eurand has had four products approved by the FDA since 2000 and has a pipeline of product candidates in development for itself and its collaboration partners. Eurand's technology platforms include bioavailability enhancement of poorly soluble drugs, customized release, taste-making/fast-dissolving formulations and drug conjugation.

Eurand is a global company with facilities in the USA and Europe. For more information, visit Eurand's website at www.eurand.com.

This release, and oral statements made with respect to informatio
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Eurand to Present Zentase Phase III Data
2. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
3. Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid Arthritis
4. Gabapentin Shown Effective for Fibromyalgia Pain
5. ApoCells Cancer Predictive Index Helps Oncologists Select the Most Effective Targeted Drug Therapy
6. Roxro Pharma’s Novel Intranasal Pain Reliever Effective, Well Tolerated in Phase 3 Study
7. XYOTAX More Cost Effective With Fewer Side Effects Than Gemcitabine or Vinorelbine in Treating Non-Small Cell Lung Cancer
8. Soliris Effective in PNH Patients With History of Aplastic Anemia and Myelodysplastic Syndromes
9. Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and Effective in Colorectal Cancer with Liver Metastases
10. Biotheras Imprime PGG Enhanced Effectiveness of Avastin in Cancer Study
11. Targanta Study Shows Oritavancin Treatment Effective in a Mouse Model of Anthrax
Post Your Comments:
(Date:5/6/2015)... Calif. , May 6, 2015 ... biotechnology company in the emerging field of regenerative ... a meeting with the investment community to review ... cells) in spinal cord injury on Friday, May ... 1/2a clinical trial and future planned clinical activities ...
(Date:5/6/2015)... BioPharma, Inc. (PDL) (NASDAQ: PDLI ) today reported ... Total revenues for the first quarter ... $136.8 million in the first quarter of 2014. Revenues ... million in royalty and license payments from PDL,s licensees ... net royalty payments from acquired royalty rights and a ...
(Date:5/6/2015)... PHILADELPHIA, May 6, 2015 Lannett Company, Inc. ... its fiscal 2015 third quarter ended March 31, 2015.  ... net sales rose 24% to $99.4 million from $80.0 ... 35% to $75.6 million, or 76% of net sales, ... and development (R&D) expenses decreased to $9.2 million from ...
Breaking Medicine Technology:Asterias Biotherapeutics to Host Investor Meeting to Review Clinical Development Strategy for AST-OPC1 in Spinal Cord Injury 2Asterias Biotherapeutics to Host Investor Meeting to Review Clinical Development Strategy for AST-OPC1 in Spinal Cord Injury 3PDL BioPharma Announces First Quarter 2015 Financial Results 2PDL BioPharma Announces First Quarter 2015 Financial Results 3PDL BioPharma Announces First Quarter 2015 Financial Results 4PDL BioPharma Announces First Quarter 2015 Financial Results 5PDL BioPharma Announces First Quarter 2015 Financial Results 6PDL BioPharma Announces First Quarter 2015 Financial Results 7Lannett Reports Strong Fiscal 2015 Third-quarter Financial Results 2Lannett Reports Strong Fiscal 2015 Third-quarter Financial Results 3Lannett Reports Strong Fiscal 2015 Third-quarter Financial Results 4Lannett Reports Strong Fiscal 2015 Third-quarter Financial Results 5Lannett Reports Strong Fiscal 2015 Third-quarter Financial Results 6Lannett Reports Strong Fiscal 2015 Third-quarter Financial Results 7Lannett Reports Strong Fiscal 2015 Third-quarter Financial Results 8
... Marken, a leading logistics specialist supporting the life science industry, today announced ... office will handle the growing demand for management and support of Marken,s Japanese ... "Opening our ... science companies in Japan and across the Asia Pacific ...
... NEWTON, Mass. , Aug. 5 Microfluidics International Corporation (OTC Bulletin Board: ... Tuesday, August 10, 2010 , at 8:30am ET . , ... (Logo: http://photos.prnewswire.com/prnh/20090811/NE59652LOGO ) , , , ... ) , , , ...
Cached Medicine Technology:Microfluidics International Corporation to Report Second Quarter 2010 Financial Results on August 10, 2010 2Microfluidics International Corporation to Report Second Quarter 2010 Financial Results on August 10, 2010 3Microfluidics International Corporation to Report Second Quarter 2010 Financial Results on August 10, 2010 4
(Date:5/6/2015)... Edvance360 LMS-SN , a leader in ... Software & Information Industry Association's (SIIA) 30th annual ... Learning Management Solution" category. Edvance360 LMS-SN won the ... this award seven years running, continued proof that Edvance360 ... industry. , "The honor of being a CODiE ...
(Date:5/6/2015)... Qushanna Doby (20) was arrested for child ... center in Florida while under the influence of Flakka, according ... tapes released by CBS4’s Peter D’Oench records Doby distraught in ... is around one year old. The drug treatment center in ... not named. The residents polled by CBS Miami express concern ...
(Date:5/6/2015)... BC (PRWEB) May 06, 2015 ... hydrotherapy supplier, is excited to announce a new ... help reduce the industry’s carbon footprint while improving ... kits feature Eco-Flex™, the world’s first ... is a game-changer for hydrotherapists,” claims the company’s ...
(Date:5/6/2015)... 06, 2015 “ SideChef ” was featured on ... at the latest and coolest applications on the market for iOS, ... expert, conducted the app review and shared with viewers how this ... day when to be a good navigator people had to know ... now everyone is a master navigator. Well what if people could ...
(Date:5/6/2015)... 06, 2015 vcfo, a specialized consulting ... and operational support to optimize business performance and productivity, ... Lynch and Michael Scheaffer. Both Lynch and Scheaffer have ... experience. , “We are delighted to add Jack ... CEO. “Leveraging their background in financial management and leadership, ...
Breaking Medicine News(10 mins):Health News:Edvance360 Wins 2015 CODiE Award for Best LMS, Winning Twice and Maintaining Finalist Status for Seven Years Running 2Health News:Edvance360 Wins 2015 CODiE Award for Best LMS, Winning Twice and Maintaining Finalist Status for Seven Years Running 3Health News:Flakka Induced Mother Abandons Baby, found by Florida Drug Treatment Center; New Video Released 2Health News:World’s First Compact Colon Hydrotherapy Speculum Kit 2Health News:World’s First Compact Colon Hydrotherapy Speculum Kit 3Health News:An Application to Guide Users through Recipes Was Featured on NewsWatch Television 2Health News:vcfo Adds Two Senior Executives to Growing Team 2
... , CAMBRIDGE, Mass., Sept. 9 ... enterprise content compliance software solutions for ... Software-as-a-Service (SaaS) solution for managing clinical trial disclosure requirements. The ... a robust offering that automates compliance with global regulatory mandates ...
... , NASHVILLE, Tenn., Sept. 9 ... provider of revenue and payment cycle management solutions, today ... Healthcare Network Accreditation Program (HNAP) from the Electronic Healthcare ... in health data processing and transactions and indicates compliance ...
... STOCKHOLM, September 9 Karolinska Development ... that will commercialize its,dermatology and wound healing opportunities as ... all of its,holdings from its five dermatology and wound ... company. , "This is a ...
... New Hearing ... ... website www.AdviceOnHearingAids.com is proving to be a valuable and informative resource for consumers ... aids, and so many different brands, styles, types of technology, and opinions about which one ...
... , TITUSVILLE, N.J., Sept. 9 Attention ... percent of children(1) and 4 percent of adults in the U.S.(2) ... 20 percent of U.S. school-aged children meet the Diagnostic and Statistical ... receiving an ADHD diagnosis.(3) Meanwhile, it is estimated that just 15 ...
... , , , HERMOSA ... empower parents across the globe to participate in the fight against AIDS ... ... go outside, go discover, go experience. Through the new partnership with ... to not only improve their own lives, but also the lives of ...
Cached Medicine News:Health News:Virtify Delivers SaaS Clinical Trial Disclosure Solution for Mid-Market Life Sciences Companies 2Health News:Virtify Delivers SaaS Clinical Trial Disclosure Solution for Mid-Market Life Sciences Companies 3Health News:Virtify Delivers SaaS Clinical Trial Disclosure Solution for Mid-Market Life Sciences Companies 4Health News:Emdeon Receives EHNAC Healthcare Network Re-accreditation 2Health News:Emdeon Receives EHNAC Healthcare Network Re-accreditation 3Health News:Karolinska Development Introduces New Concept for Development of its Dermatology and Wound Healing Portfolio 2Health News:Help for Hearing Loss - Now Available Online 2Health News:Help for Hearing Loss - Now Available Online 3Health News:CONCERTA(R) (methylphenidate HCI) LAUNCHES MOBILE WEB EXPERIENCE TO PROVIDE TOOLS AND SUPPORT FOR ADHD AWARENESS 2Health News:CONCERTA(R) (methylphenidate HCI) LAUNCHES MOBILE WEB EXPERIENCE TO PROVIDE TOOLS AND SUPPORT FOR ADHD AWARENESS 3Health News:CONCERTA(R) (methylphenidate HCI) LAUNCHES MOBILE WEB EXPERIENCE TO PROVIDE TOOLS AND SUPPORT FOR ADHD AWARENESS 4Health News:CONCERTA(R) (methylphenidate HCI) LAUNCHES MOBILE WEB EXPERIENCE TO PROVIDE TOOLS AND SUPPORT FOR ADHD AWARENESS 5Health News:'Go and Good Things Happen' with (BUGABOO)(RED) 2Health News:'Go and Good Things Happen' with (BUGABOO)(RED) 3Health News:'Go and Good Things Happen' with (BUGABOO)(RED) 4
... to the National Academy of ... use of cardiac markers in ... is definitive of acute myocardial ... assay was designed for rapid ...
A fluorogenic enzyme-linked immunoassay (ELISA) for the quantitative measurement of myoglobin in human serum or plasma aiding in the diagnosis of acute myocardial infarction (AMI). Features : Dry che...
Clinical marker immunoassay kit for detection of Myoglobin....
AxSYM Myoglobin is a Microparticle Enzyme Immunoassay (MEIA) for the quantitative determination of myoglobin in human serum or plasma on the AxSYM System....
Medicine Products: